Phase II trial of neoadjuvant temozolomide in resectable melanoma patients Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Dacarbazine
  • Melanoma

abstract

  • The response proportion to TMZ in the neoadjuvant setting was 16%, not different than in the metastatic setting. Responses were seen even in tumors with a methylated MGMT promoter. Pretreatment cryopreserved tumor adequate for microarray analysis could be obtained in most, but not all, patients. Post-treatment tumor was unavailable in complete responders.

publication date

  • January 15, 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1093/annonc/mdp593

PubMed ID

  • 20080829

Additional Document Info

start page

  • 1718

end page

  • 22

volume

  • 21

number

  • 8